EP1616182A4 - Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 - Google Patents
Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2Info
- Publication number
- EP1616182A4 EP1616182A4 EP04757538A EP04757538A EP1616182A4 EP 1616182 A4 EP1616182 A4 EP 1616182A4 EP 04757538 A EP04757538 A EP 04757538A EP 04757538 A EP04757538 A EP 04757538A EP 1616182 A4 EP1616182 A4 EP 1616182A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- beta
- type
- replacement therapy
- hydroxysteroid dehydrogenase
- enzyme replacement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
- A61K51/1234—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45545703P | 2003-03-18 | 2003-03-18 | |
PCT/US2004/008083 WO2004082627A2 (en) | 2003-03-18 | 2004-03-17 | ENZYME REPLACEMENT THERAPY WITH 17-β-HYDROXYSTEROID DEHYDROGENASE-TYPE 2 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1616182A2 EP1616182A2 (en) | 2006-01-18 |
EP1616182A4 true EP1616182A4 (en) | 2008-04-16 |
Family
ID=33030003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04757538A Withdrawn EP1616182A4 (en) | 2003-03-18 | 2004-03-17 | Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1616182A4 (en) |
WO (1) | WO2004082627A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006247143B2 (en) * | 2005-05-18 | 2013-07-18 | Biofactura, Inc. | Compositions and methods for metabolic selection of transfected cells |
US8920775B2 (en) | 2009-07-17 | 2014-12-30 | Technical University Of Denmark | Loading technique for preparing radionuclide containing nanoparticles |
EP2651447B1 (en) | 2010-12-14 | 2018-08-29 | Technical University of Denmark | Entrapment of radionuclides in nanoparticle compositions |
DE102012002929A1 (en) * | 2012-02-14 | 2013-08-14 | Jürgen Lewald | Analyzing a peripheral blood sample of a female subject based on concentration of a steroid hormone that indicates endometriosis, comprising e.g. testosterone, progesterone, cortisol, dehydroepiandrosterone and androstenedione |
CN113280980B (en) * | 2021-04-27 | 2022-07-01 | 中国原子能科学研究院 | Target detection method and device |
-
2004
- 2004-03-17 EP EP04757538A patent/EP1616182A4/en not_active Withdrawn
- 2004-03-17 WO PCT/US2004/008083 patent/WO2004082627A2/en active Application Filing
Non-Patent Citations (4)
Title |
---|
BULUN S E ET AL: "Mechanisms of excessive estrogen formation in endometriosis", JOURNAL OF REPRODUCTIVE IMMUNOLOGY, ELSEVIER SCIENCE IRELAND LTD, IE, vol. 55, 2002, pages 21 - 33, XP002983135, ISSN: 0165-0378 * |
KITAWAKI J ET AL: "Endometriosis: The pathophysiology as an estrogen-dependent disease.", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 83, no. 1-5, December 2002 (2002-12-01), pages 149 - 155, XP002470931, ISSN: 0960-0760 * |
UTSUNOMIYA HIROKI ET AL: "The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, ENDOCRINE SOCIETY, CHEVY CHASE, MD, US, vol. 86, no. 7, July 2001 (2001-07-01), pages 3436 - 3443, XP009096560, ISSN: 0021-972X * |
ZEITOUN KM ET AL: "Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target", FERTILITY AND STERILITY, ELSEVIER SCIENCE INC, NEW YORK, NY, US, vol. 72, no. 6, December 1999 (1999-12-01), pages 961 - 969, XP002211657, ISSN: 0015-0282 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004082627A2 (en) | 2004-09-30 |
WO2004082627A3 (en) | 2005-03-10 |
EP1616182A2 (en) | 2006-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU0302451D0 (en) | New compounds with therapeutic effect | |
GB2405115B (en) | Hole-saw assembly including two hole-saws | |
GB2387387B (en) | Stabilizer mixtures | |
GB0309138D0 (en) | Design 2 | |
GB0312517D0 (en) | Embroidered electrode | |
AU2003274975A8 (en) | Electrooptic assembly | |
AU2003238930A8 (en) | Enzymes | |
EP1490074A4 (en) | Mixed- cell gene therapy | |
AU2003275501A8 (en) | Drive arrangement | |
ZA200707236B (en) | Microorganisms for therapy | |
GB0327384D0 (en) | Gene therapy | |
EP1616182A4 (en) | Enzyme replacement therapy with 17-beta-hydroxysteroid dehydrogenase-type 2 | |
GB2389535B (en) | Incubator | |
EP1614746A4 (en) | Fructosylamine oxidase | |
AU2003216376A8 (en) | Enzymes | |
AU2003294705A8 (en) | Ntsm gene | |
GB2387883B (en) | Drive arrangement | |
GB0213745D0 (en) | Enzyme | |
AU2003220607A8 (en) | Enzymes | |
AU2003225282A8 (en) | Enzymes | |
GB2413329B (en) | Novel Enzymes | |
GB0320121D0 (en) | Marketing scheme | |
GB0309136D0 (en) | Design 1 | |
GB0310457D0 (en) | Enzyme | |
EP1514924A4 (en) | Novel acylase gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051018 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 5/24 20060101ALI20080306BHEP Ipc: G01N 33/53 20060101AFI20050330BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20080317 |
|
17Q | First examination report despatched |
Effective date: 20090327 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090807 |